Silco Pharmaceuticals Limited (DSE:SILCOPHL)

Market Cap	1.68B +10.2%
Revenue (ttm)	431.04M +0.3%
Net Income	42.40M -15.1%
EPS	0.41 -14.8%
Shares Out	103.81M
PE Ratio	39.49
Forward PE	n/a
Dividend	0.11 (0.68%)
Ex-Dividend Date	Dec 17, 2025

Volume	658,014
Open	16.20
Previous Close	16.20
Day's Range	16.00 - 16.40
52-Week Range	11.10 - 18.50
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 29, 2026

About Silco Pharmaceuticals

Silco Pharmaceuticals Limited engages in manufacturing and marketing of finished pharmaceutical products in Bangladesh and internationally. It offers products in the therapeutic areas of analgesic and antipyretic, anti-platelet, antiasthmatic, antibiotic, antidepressant, antidiabetic, antiemetic, antifungal, antihistamin, antihypertensive and antianginal, antimicrobial, antiprotozoal, antispasmodic, antiulcerant, anxiolytic, calcium and combinations, central muscle relaxants, diuretics, gastroprokinetic, haematinic, vitamins and minerals, laxat...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 313
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: SILCOPHL

Financial Performance

In fiscal year 2025, Silco Pharmaceuticals's revenue was 431.54 million, an increase of 5.23% compared to the previous year's 410.10 million. Earnings were 42.65 million, a decrease of -7.04%.